Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Yervoy
Biotech
Jounce gets trounced as phase 2 data disappoint once again
Jounce is reevaluating a top monoclonal antibody program after it failed to adequately reduce tumor size in combination with another lead asset.
Max Bayer
Aug 31, 2022 7:30am
BMS melanoma, genitourinary commercial lead heads to miR
Aug 13, 2021 9:45am
BMS' LAG-3 drug boosts Opdivo in staving off melanoma
May 19, 2021 5:00pm
Idera's TLR9 drug flunks melanoma phase 3, tanking stock
Mar 19, 2021 8:45am
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
Feb 24, 2021 8:00am
Jounce sinks as it ditches phase 2 Yervoy combo trial
Nov 3, 2020 9:55am